Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A W Tong

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Cancer Gene Therapy|March 29, 2008
Modulation of miRNA activity in human cancer: a new paradigm for cancer gene therapy?A W Tong, J Nemunaitis
Leukemia & Lymphoma|March 1, 1996
CD40 and the effect of anti-CD40-binding on human multiple myeloma clonogenicityA W Tong, M J Stone
Methods in Molecular Medicine|March 11, 2011
Anti-K-ras1 Ribozyme Adenoviral Vector for Gene Therapy of Non-Small Cell Lung CancerY A Zhang, J Nemunaitis, A W Tong
Molecular Biotechnology|July 27, 2000
Generation of a ribozyme-adenoviral vector against K-ras mutant human lung cancer cellsY A Zhang, J Nemunaitis, A W Tong
Cancer Research|November 1, 1984
Characterization of two human small cell lung carcinoma-reactive monoclonal antibodies generated by a novel immunization approachA W Tong, J Lee, M J Stone
Journal of the National Cancer Institute|November 1, 1986
Discrimination of human small cell and non-small cell lung tumors by a panel of monoclonal antibodiesA W Tong, J C Lee, M J Stone
Blood|January 1, 1987
Characterization of a monoclonal antibody having selective reactivity with normal and neoplastic plasma cellsA W Tong, J C Lee, M J Stone
Gene Therapy|February 15, 2001
Anti-tumorigenic effect of a K-ras ribozyme against human lung cancer cell line heterotransplants in nude miceY A Zhang, J Nemunaitis, K J Scanlon, et al.
Cancer Detection and Prevention|January 1, 1988
Selective depletion of human myeloma clonogenic stem cells from bone marrow cell preparations by a plasma-cell reactive antibody and complementM J Stone, A W Tong, J W Fay, et al.
Blood|November 1, 1987
Elimination of clonogenic stem cells from human multiple myeloma cell lines by a plasma cell-reactive monoclonal antibody and complementA W Tong, J C Lee, J W Fay, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Cancer Gene Therapy|March 29, 2008
Modulation of miRNA activity in human cancer: a new paradigm for cancer gene therapy?A W Tong, J Nemunaitis
Leukemia & Lymphoma|March 1, 1996
CD40 and the effect of anti-CD40-binding on human multiple myeloma clonogenicityA W Tong, M J Stone
Methods in Molecular Medicine|March 11, 2011
Anti-K-ras1 Ribozyme Adenoviral Vector for Gene Therapy of Non-Small Cell Lung CancerY A Zhang, J Nemunaitis, A W Tong
Molecular Biotechnology|July 27, 2000
Generation of a ribozyme-adenoviral vector against K-ras mutant human lung cancer cellsY A Zhang, J Nemunaitis, A W Tong
Cancer Research|November 1, 1984
Characterization of two human small cell lung carcinoma-reactive monoclonal antibodies generated by a novel immunization approachA W Tong, J Lee, M J Stone
Journal of the National Cancer Institute|November 1, 1986
Discrimination of human small cell and non-small cell lung tumors by a panel of monoclonal antibodiesA W Tong, J C Lee, M J Stone
Blood|January 1, 1987
Characterization of a monoclonal antibody having selective reactivity with normal and neoplastic plasma cellsA W Tong, J C Lee, M J Stone
Gene Therapy|February 15, 2001
Anti-tumorigenic effect of a K-ras ribozyme against human lung cancer cell line heterotransplants in nude miceY A Zhang, J Nemunaitis, K J Scanlon, et al.
Cancer Detection and Prevention|January 1, 1988
Selective depletion of human myeloma clonogenic stem cells from bone marrow cell preparations by a plasma-cell reactive antibody and complementM J Stone, A W Tong, J W Fay, et al.
Blood|November 1, 1987
Elimination of clonogenic stem cells from human multiple myeloma cell lines by a plasma cell-reactive monoclonal antibody and complementA W Tong, J C Lee, J W Fay, et al.
Pageof 3